Aspen Neuroscience/$ASPE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aspen Neuroscience
Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson's disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells.
- Ticker
- $ASPE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 122
- Headquarters
- San Diego, United States
- Website
- www.aspenneuroscience.com
ASPE Metrics
BasicAdvanced
$402M
-
-$6.29
-
-
Price and volume
Market cap
$402M
52-week high
$14.90
52-week low
$11.20
Financial strength
Current ratio
4.562
Quick ratio
4.426
Long term debt to equity
0.071
Total debt to equity
0.111
Profitability
EBITDA (TTM)
-64.923
Management effectiveness
Valuation
Price to book
-0.6
Price to tangible book (TTM)
-0.6
Price to free cash flow (TTM)
-2.207
Free cash flow yield (TTM)
-45.32%
Free cash flow per share (TTM)
-6.263
Growth
Bulls say / Bears say
In Aspen’s 15-patient Phase 1/2a trial, the company reports sustained improvements in motor and quality-of-life measures, with average results above its stated clinical-meaningfulness benchmarks at some follow-ups. This is an early signal that sasineprocel could offer more than symptom management. (SEC)
The FDA granted sasineprocel RMAT designation, giving Aspen more structured interaction with regulators and potential access to expedited review pathways. That may help guide development, although it does not guarantee approval or a faster process. (Aspen Neuroscience)
Aspen says its newer trial cohorts use a cryopreserved “thaw-and-inject” formulation intended to simplify delivery and support scalable production. A recent peer-reviewed paper also reported reproducible quality controls across patient-derived cell lines, addressing one key challenge for personalised cell therapy. (Aspen Neuroscience, Cell Stem Cell)
The encouraging efficacy results come from a small, open-label study with no control group, so expectations, disease variation and other factors could influence the results. Aspen also says its clinical-meaningfulness benchmarks have not been agreed with regulators or independently validated. (SEC)
Even after the IPO, Aspen expects its funds to last only into the second half of 2028 and says it will need more capital to advance its candidates. It does not expect product revenue for many years, if at all, leaving shareholders exposed to further fundraising and dilution. (SEC)
Aspen faces a competitor already in Phase 3: Bayer’s off-the-shelf cell therapy can be administered without waiting for a patient-specific product to be made. That could put Aspen at a timing and convenience disadvantage if both programmes succeed. (IFR)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
ASPE Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.